Viewing nowGaba Newro Capsule 25 mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
Hankook Pharmaceutical Co., Ltd.

MFDS item code 201901391 · Approved 2019.03.07 · Insurance code 645306070
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also used as an adjunctive treatment in patients with epilepsy for partial seizures, effective whether or not accompanied by secondary generalization. Additionally, it is utilized in the treatment of fibromyalgia. It is effective for various neurological disorders and pain conditions, helping improve patients' symptoms.
This medicine should be administered orally as the total daily dose of pregabalin divided into 2 doses, regardless of food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation’) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg per day. Based on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); based on efficacy and tolerability, the dose may be increased to 150 mg twice daily (300 mg per day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased to 225 mg twice daily (450 mg per day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is excreted primarily by the kidneys in unchanged form. Clearance of this medicine is directly affected by creatinine clearance; therefore, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an additional supplemental dose should be administered promptly after every 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function ≥60 (mL/min): starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID ≥30 -<60 (mL/min): starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID ≥15 -<30 (mL/min): starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID <15 (mL/min): starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25 (mg), 100 (mg), single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the dosing regimen. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (aged 65 years and older) Dose reduction may be necessary in elderly patients with impaired renal function.
Safety and efficacy data are insufficient for children under 12 years of age and adolescent patients aged 12 ~17 years; therefore, use is not recommended.
This drug may increase the risk of suicidal thoughts or behaviors, so any changes in mood or behavior during treatment should be reported immediately to a healthcare provider. Individuals allergic to pregabalin or any component of this drug should not take it, and it should also be avoided in cases of certain genetic disorders like lactose intolerance. Diabetic patients should be cautious as weight gain may necessitate adjustments in blood sugar control medications. If any signs of angioedema appear, the drug should be stopped immediately, and elderly patients should be careful due to the risk of falls from dizziness and drowsiness. Visual disturbances such as blurred vision may occur, and these symptoms may improve after discontinuation of the medication. If pregabalin is suddenly stopped, withdrawal symptoms like insomnia, headaches, and anxiety may appear, so it should be tapered gradually in consultation with a healthcare provider. Patients with a history of drug abuse have a higher risk of misuse or dependence on this drug, and caution should be exercised during use. Patients with impaired kidney function may require dose adjustments. Patients with heart disease should be cautious when taking this drug, and co-administration with opioid analgesics may increase the risk of central nervous system depression. In early pregnancy, there is a risk of fetal malformation, so women who are pregnant or planning to become pregnant should ensure they consult their healthcare provider before taking this medication and should use effective contraception. Breastfeeding women should discuss with their healthcare provider whether to discontinue breastfeeding or the medication as this drug may pass into breast milk. Dizziness and drowsiness may occur during treatment, so driving or operating hazardous machinery should be avoided until symptoms are resolved. In the event of an overdose, symptoms such as confusion, drowsiness, or depression may appear, so contact a medical professional immediately for appropriate treatment. Keep out of reach of children and ensure it is not transferred to other containers.
Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, changes in vision, insomnia, headache, nausea, anxiety, diarrhea, influenza-like syndrome, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, rhinitis, neutropenia, increased appetite, decreased appetite, hypoglycemia, confusion, disorientation, irritability, melancholy, euphoria, reduced libido, insomnia, depersonalization, sexual arousal disorder, restlessness, anxiety, mood disturbance, emotional decline, emotional elevation, difficulty finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, inability to suppress impulses, apathy, dizziness, drowsiness, ataxia, motor coordination disturbances, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, somnolence, cognitive impairment, nystagmus, speech disorders, myoclonus, reflex reduction, movement disorders, psychomotor agitation, position-related dizziness, hypersensitivity, burning sensation, activity tremor, syncope, confusion, exercise intolerance, smell disturbances, taste loss, writing difficulties, blurred vision, diplopia, indirect vision loss, visual disturbances, visual field defects, photophobia, dry eyes, conjunctival edema, decreased vision, eye pain, eye fatigue, increased tear secretion, ocular irritation, pupil dilation, vibration-related changes in depth perception, strabismus, brightness of vision, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweat, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urinary disorders, incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, breast discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling drunk, altered sensations, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased serum alanine aminotransferase, elevated serum creatine phosphokinase, increased aspartate aminotransferase, elevated blood sugar, reduction in platelet count, decreased serum potassium, weight loss, elevated serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis, mood disorders, drowsiness, confusional state, depression, agitation, restlessness, exacerbation of seizures, ataxia, speech difficulties, sensory disturbances, memory impairment, sleep disorders, skin diseases, increased BUN, blood in stools, tinnitus
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly sealed container to prevent moisture or air exposure, preferably in a cool place between 15 and 30 degrees Celsius. Proper storage will help to maintain the drug's effectiveness.
A capsule with a pale yellow upper part and a white lower part containing a white or light yellow powder.
30 capsules/bottle, 100 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 25mg
Hard capsule · Prescription medication
Hankook Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.